CHINA NATIONAL MEDICINES CORPORATION LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.6 CNY | -0.94% |
|
-0.42% | +6.92% |
Strengths
- With a P/E ratio at 9.62 for the current year and 8.82 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +6.92% | 3.18B | C+ | ||
| -6.59% | 22.92B | C+ | ||
| +14.17% | 8.74B | B | ||
| -2.89% | 7.94B | C | ||
| -33.14% | 6.69B | B- | ||
| +22.28% | 5.66B | B- | ||
| +3.99% | 4.22B | B | ||
| -4.28% | 4.02B | B- | ||
| +12.80% | 3.41B | C | ||
| -13.51% | 3.18B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600511 Stock
- Ratings China National Medicines Corporation Ltd.
